CTOs on the Move

ALCO Sales and Service Co.

www.alcosales.com

 
However, ALCO can make the following promises and keep them: ALCO promises to earn your trust by providing superior service and products. Good customers deserve the best and we review your orders to assure you get exactly what you ordered. Quality,
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.alcosales.com
  • 6851 High Grove Blvd
    Burr Ridge, IL USA 60527
  • Phone: 630.655.1900

Executives

Name Title Contact Details

Similar Companies

Amalgamated Life and Health

Amalgamated Life and Health is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Easter Seals Waterbury, Connecticut

Easter Seals Waterbury, Connecticut is a Waterbury, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Silver Cross Hospital

Generation after generation, families have depended upon Silver Cross Hospital to care for their loved ones. The commitment goes back to Thanksgiving Day in 1895 when the Will County Union of King`s Daughters and Sons opened the doors of a 33-bed hospital in Joliet named after their emblem the Maltese cross. Their promise was to provide quality healthcare with compassion for the citizens of Will County and surrounding communities. Today, more than a century later, Silver Cross Hospital remains true to that original promise. As the needs of the community grew, so did Silver Cross—in size and stature. Services rapidly expanded, evolved and increased in complexity. The medical staff advanced superior healthcare and attracted new expertise including specialists with Ann & Robert H. Lurie Children`s Hospital of Chicago, The Rehabilitation Institute of Chicago (RIC), University of Chicago Medicine Comprehensive Cancer Center, Northwestern Medicine for neurosciences and stroke care, and the Midwest Institute for Robotic Surgery. Silver Cross performs more robotic-assisted procedures than any other facility in the Chicago area. Surgeons from around the world come train with us. National prominence was achieved when Silver Cross- an independent healthcare provider, was first recognized as one of the nation`s 100 Top Hospitals in 2004—an accomplishment that has been repeated for seven years. And year after year, Silver Cross has been acknowledged as one of American`s Friendliest Hospitals because we treat patients the way they should be treated and for our dedication to patient safety with an “A” Hospital Safety Score from the Leapfrog Group. The mission of providing quality healthcare continues today with a remarkable 296-bed replacement hospital, which opened in 2012. All patient rooms are private—accommodating today`s medical technology and ultimately reducing unnecessary transfers and the risk of infection and injury. The hospital`s unique design creates efficiencies between departments and promotes an environment that helps patients heal faster. Our 158-acre New Lenox campus includes three medical/office buildings, University of Chicago Medicine Comprehensive Cancer Center, and an ambulatory care center opening in fall 2017. The hospital also has plans to build a 100-bed Behavioral Health Hospital to open in 2019. Over the years, Silver Cross has developed an extensive ambulatory network throughout the region that includes five satellite facilities with the independent services of many physicians and an array of outpatient services such as diagnostic imaging and rehabilitation. Silver Cross also operates a 27/7 freestanding Emergency Care Center in Homer Glen and an Urgent Care center in Joliet.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.

Chiltern

We are the leading, global mid-sized contract research organization. Our team of more than 4,200 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.